The Inaugural
CBC Accelerator Network Forum
presented by the
Chicago Biomedical Consortium

Thursday, March 30, 2017
4:00 - 7:00 PM

Gleacher Center
450 North Cityfront Plaza Drive
Chicago, Illinois 60611

The CBC gratefully acknowledges support from the Searle Funds
at The Chicago Community Trust
CBC MISSION
The mission of the Chicago Biomedical Consortium (CBC) is to stimulate collaboration among scientists at Northwestern University, The University of Chicago, the University of Illinois at Chicago and others to accelerate discovery that will transform biomedical research and improve the health of humankind. The CBC will:

- Stimulate research and education that bridge institutional boundaries,
- Enable collaborative and interdisciplinary research that is beyond the range of a single institution,
- Mentor and develop a strong cadre of biomedical leaders, researchers, and entrepreneurs in Chicago,
- Enhance and promote the development of the biomedical ecosystem in Chicago,
- Facilitate development of therapeutics that will, over the long term, improve the health of citizens of Chicago and beyond.

CBC LEADERSHIP
Lucy Godley, MD, PhD
CBC Scientific Director
The University of Chicago
Phone: 773 702-4140
Email: lgodley@medicine.bsd.uchicago.edu

Brian K. Kay, PhD
CBC Scientific Director
University of Illinois at Chicago
Phone: 312-355-0668
Email: bkay@uic.edu

Richard Morimoto, PhD
CBC Scientific Director
Northwestern University
Phone: 847-491-3340
Email: r-morimoto@northwestern.edu

Kathryn Stallcup, PhD
CBC Executive Director
Northwestern University
Phone: 847-467-0389
Email: k-stallcup@northwestern.edu

CBC STAFF
Karen Snapp, DDS, PhD
CBC Senior Associate Director
Northwestern University
Phone: 847-467-0633
Email: knapp@northwestern.edu

Kimberly Corn
CBC Associate Director, Business Operations and Finance
Northwestern University
Phone: 847-467-0357
Email: k-corn@northwestern.edu

Jola Glotzer, MD
CBC Communications Director
The University of Chicago
Phone: 773-834-5132
Email: jolaglotzer@uchicago.edu

Corinna Kitcharoen, MBA
CBC Program Coordinator
University of Illinois at Chicago
Phone: 312-996-1311
Email: ckitch1@UIC.edu

www.chicagobiomedicalconsortium.org
**INTRODUCTORY REMARKS**

*Katie Stallcup*, CBC Executive Director

---

**CBC FACULTY PRESENTATIONS**

**4:15 PM**

*Guillermo Ameer*  
Professor, Biomedical Engineering and Surgery (Vascular Surgery), McCormick School of Engineering, NU

**4:30 PM**

*Brenda Russell*  
Professor Emerita, Physiology & Biophysics, UIC

**4:45 PM**

*Chuan He*  
John T. Wilson Distinguished Service Professor, Chemistry, UChicago

---

**OPEN DISCUSSION, MODERATED BY:**

*Lucy Godley*, CBC Scientific Director, UChicago  
*Brian Kay*, CBC Scientific Director, UIC  
*Rick Morimoto*, CBC Scientific Director, NU

---

**NETWORKING**

**5:30 PM**

**NETWORKING DINNER**

**7:00 PM**

**ADJOURN**
About CBCAN

Inspired by the SPARK program at Stanford, the CBCAN program is envisioned as a community, bringing together industry experts, university tech transfer officers, and researchers with discoveries that may have commercial potential. The aim is to move promising discoveries into and forward in the pipeline towards commercialization by providing the early commercial guidance that universities and university-based researchers need (see graphic below).

- CBCAN meetings will take place quarterly in a central Chicago downtown location,
- Meetings will feature presentations of basic research that may have commercial potential,
- Participants’ feedback will be collected after each forum via online survey to continuously improve the CBCAN format,
- The CBCAN program will be central to and fully integrated with other CBC Phase 2 initiatives such as the new CBC Accelerator Award program and the new CBC Entrepreneurial Fellows (EF) program (see page 6 for program descriptions).

CBC Phase 2 will expand its support of the commercialization pipeline. The pipeline from ‘Discoveries’ to market consists of several stages such as ‘Translation to Business Application,’ ‘Company Formation’ and ‘Commercialization’ (top). In turn, ‘Translation to Business Application’ entails a number of sub-stages, including ‘Early Commercial Guidance,’ ‘Networking,’ ‘Tech Transfer,’ ‘Incubation’ and ‘Pre-Seed Funds’. During Phase 1, the CBC’s biggest effort concentrated on ‘Discoveries’ (black arrow) although all sub-stages of ‘Translation to Business Application’ have also received CBC support (red arrows). By establishing CBCAN, CBC Phase 2 will strengthen that support by providing ‘Early Commercial Guidance’ and facilitating ‘Networking’ within the Chicago biomedical ecosystem (thick red arrows).
GUILLERMO AMEER, PH.D.
Professor, Biomedical Engineering and Surgery (Vascular Surgery), McCormick School of Engineering, NU

Dr. Ameer is a professor in the Biomedical Engineering Department at the McCormick School of Engineering and the Department of Surgery at the NU Feinberg School of Medicine. He received his Bachelor’s degree in Chemical Engineering from the University of Texas at Austin and his doctoral degree in Chemical and Biomedical Engineering from MIT. His research interests include biomaterials, tissue engineering, regenerative engineering; on-demand, patient-specific medical devices, controlled drug delivery, and bio/nanotechnology for improved therapeutics and diagnostics. Specifically, Dr. Ameer’s laboratory pioneered the development and applications of citrate-based biomaterials. He has co-authored over 250 peer-reviewed journal publications and conference abstracts, several book chapters, and has over 40 patents issued and pending in 9 countries, many of which have been licensed to develop innovative medical products. Dr. Ameer is a Fellow of the American Institute of Medical and Biological Engineering and a Fellow of the Biomedical Engineering Society. He is a member of the Scientific Advisory Board of Acuitive Technologies, Inc. and was the co-founder of several medical device companies in the areas of dialysis, vascular surgery, and orthopedic surgery.

CHUAN HE, PH.D.
John T. Wilson Distinguished Service Professor, Chemistry, UChicago

Dr. He is Professor and Director of the Institute for Biophysical Dynamics at UChicago, and an HHMI Investigator. He attended the University of Science and Technology of China and graduated with a B.S. in Chemistry in 1994. After his Ph.D. training with Professor Stephen J. Lippard at MIT, he worked with Professor Gregory L. Verdine as a Damon Runyon Postdoctoral Fellow at Harvard University. He started his independent career in the Department of Chemistry at UChicago in 2002. Dr. He is best known for his work in discovering and deciphering reversible RNA methylation in post-transcriptional gene expression regulation. Dr. He’s laboratory also studies DNA methylation. Dr. He invented TAB-seq, a method that can map 5-hydroxymethylcytosine (5hmC) at base-resolution genome-wide, as well as hmcC-Seal, a method that covalently labels 5hmC for its detection and profiling. Together with two other research groups, Dr. He and co-workers have revealed the DNA N6-methyldeoxyadenosine as a new methylation mark that could affect gene expression in eukaryotes. Dr. He’s notable awards include Searle Scholar Award (2003) and Beckman Young Investigators Award (2005). Dr. He is a founder of a Chicago-based startup WiseGene.

BRENDA RUSSELL, PH.D.
Professor Emerita, Physiology & Biophysics, UIC

Dr. Russell is Professor Emerita of Physiology and Biophysics, and formerly Professor of Bioengineering and Medicine at UIC. She has ongoing NIH funding and an active research group. Dr. Russell received her Ph.D. in Physiology in 1971, under the direction of Professor Sir Andrew Huxley (Nobel Laureate), at the University of London, England. She has done research on muscle adaptation at Duke, UCLA, Rush University and UIC, and has served on Study Sections for the NIH and the American Heart Association. She was the recipient of the 2010 iBIO Institute iCON Innovator Award, considered by many to be the region’s most prestigious honor for life sciences educators, researchers, and entrepreneurs. Dr. Russell is a former editor of The American Journal of Physiology: Cell Section; Cell & Tissue Research, and editorial board member of many journals, including Circulation Research and The Journal of Applied Physiology. Dr. Russell and Dr. Tejal Desai (UCSF) founded Cell Habitats, Inc, an early-stage biomedical device company developing an easy-to-administer microdevice that allows the natural repair and regeneration of damaged tissue. Its first application will be to restore normal cardiac function after a heart attack. They have approved patents in this area.
To align CBC’s strengths with the Searle Consultants’ strategy to “promote a new infrastructure for success for the Chicago biomedical industry,” the CBC will introduce new initiatives in Phase 2 (2017-2021). Some of the programs that have been initiated in Phase 1 will continue to be offered during Phase 2 as well.

ACCELERATOR AWARD

The CBC will launch a new Accelerator Award program to support translational research and provide university researchers with “early commercial guidance.” Accelerator Awards will be used to support the initial, and therefore highest risk, stage of commercially-directed research. Domain Experts from industry will participate in the selection of projects and may provide advice to award recipients in setting and progressing toward commercialization milestones. The program will consist of two parts (A and B):

• **Part A:** Translational research projects will be evaluated by a team of reviewers that will include industry scientists. The application process will include an oral presentation at a CBCAN meeting. Full proposals must discuss commercial potential, including milestones and deliverables. Accelerator Part A awards will be for $100,000 for one year.

• **Part B:** Only projects that have met proposed milestones during Part A awards will be invited to apply for $150,000 for one additional year.

• Applicants must be faculty with research programs at the CBC universities.

• Projects involving multi-institutional collaborative teams will be given strong preference, although collaboration will not be required. Collaborations could involve faculty scientists at any Chicago-area university, but all institutions receiving CBC funding must agree to waive indirect cost recovery.

EDUCATION AND OUTREACH

The CBC will continue to convene the local biomedical research community, including at the annual CBC Symposium, and provide the CBC website as an essential informational tool for the growing community.
ENTREPRENEURIAL FELLOWS (EF)

A new CBC Entrepreneurial Fellows (EF) program will identify and support a cohort of postdoctoral fellows who are keen to work in the biotech start-up space of Chicago.

- Applications must be jointly submitted by a CBC university faculty member and a postdoctoral fellow candidate.
- Projects must be related to biomedicine, preferably pertaining to development of therapeutics or diagnostics.
- Projects must have clear translational milestones.
- The faculty mentor must agree that the fellow will have significant time available for professional development activities.
- Applications will be evaluated by the EP Review Board, composed of Tech Transfer Officers, industry experts, and faculty members who will consider both potential commercial value and scientific merit.
- Fellowship awards will be for 12 months. If proposed milestones have been met and reasonable next steps are proposed, Fellows may apply for a second year of funding.
- EP Awards will be for $90,000 per year, to cover a salary of $65,000 and benefits.

CATALYST AWARD

The successful CBC Catalyst Award program will be continued, supporting the essential inputs into the commercialization pipeline by funding innovative collaborative research.

- Awards will provide up to $250,000 for up to two years, for basic biomedical research. Research with translational potential will receive special consideration.
- Applicants must be tenured or tenure-track faculty with research programs at the CBC universities who will initiate a new collaboration.
- Research proposals must have Co-Principal Investigators from at least two of the three CBC universities.